February 17, 2026 / Sciad Communications / Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou ...
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...
This includes the labeling of the dCas9 protein, engineering of sgRNA, and the use of dCas9 orthologs from different bacterial species. CRISPR, clustered regularly interspaced short palindromic ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, ...
SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
DUBLIN--(BUSINESS WIRE)--The "CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering. The global landscape of medical therapies is ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results